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Ability of mechanical reperfusion to salvage
myocardium in patients with acute myocardial
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of symptoms
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Investigators Florence, Italy; and Munich, GermanyBackground The ability of primary percutaneous coronary intervention (PCI) to salvage myocardium in patients
with acute ST-segment elevation myocardial infarction (STEMI) presenting N12 hours after symptom onset is questionable.
The aim of this study was to assess the ability of primary PCI to salvage myocardium in patients with STEMI presenting
between 12 and 48 hours after the symptom onset.
Methods In the BRAVE-2 trial, 365 patients with acute STEMI presenting between 12 and 48 hours from the symptom
onset were randomized to an invasive (PCI) or a conservative treatment strategy. Two-hundred sixty-one patients enrolled
in 2 centers had scintigraphy before randomization and 5 to 10 days later and constitute the cohort of the present
study. Salvage index (proportion of initial perfusion defect salvaged) was the primary end point of this study.
Results There were 131 patients randomly assigned to the invasive treatment and 130 patients assigned to the
conservative treatment. Initial perfusion defect (median [25th-75th percentiles]) did not differ between groups (17.0%
[9.0-28.5] vs 16.0% [9.0-37.5] of the left ventricle; P = .99). The final infarct size, measured in the follow-up scintigraphy,
was significantly smaller in patients assigned to the invasive treatment than in those assigned to the conservative
treatment (8.0% [2.0-16.0] vs 12.0% [3.2-25.0] of the left ventricle; P = .004). Salvage index was 0.44 (0.13-0.80) in the
invasive group versus 0.23 (0.0-0.50) in the conservative group ( P b .001).
Conclusion Primary PCI leads to significant myocardial salvage in patients with STEMI presenting between 12 and 48
hours after symptom onset. (Am Heart J 2006;152:113329.)Information available indicates that percutaneous
coronary interventions (PCIs) are effective even when
performed in patients with acute myocardial infarction
after 12 hours from symptom onset.1,2 Experimental3
and clinical4-6 studies have demonstrated that ischemic
but viable myocardium can persist for N12 hours after
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doi:10.1016/j.ahj.2006.08.007these studies indicate that in patients with ST-segment
elevation acute myocardial infarction (STEMI) there is a
potential for myocardium salvage even after the first
12 hours from the symptom onset given the appropriate
reperfusion approach is used.
The BRAVE-2 trial7 included patients with STEMI
presenting between 12 to 48 hours after symptom onset.
The trial demonstrated that patients treated by primary
PCI show smaller infarct size compared with patients
who received conservative therapy. The aim of this
study was to assess the ability of primary PCI to salvage
myocardium in patients with STEMI presenting between
12 and 48 hours after the symptom onset.
Methods
Patients and treatments
The BRAVE-2 trial7 was a randomized, multicenter trial that
included STEMI patients presenting between 12 to 48 hours
from the onset of chest pain recruited between May 2003 and





(n = 104) P
Age, median (IQR), y 65.8 (54.7-73.8) 67.1 (59.2-73.4) .50
Women 68 (26.1) 27 (26.0) .98
Arterial hypertension 179 (68.6) 69 (66.3) .68
Diabetes 61 (23.4) 26 (25.0) .63
Current smoker 94 (36.0) 36 (34.6) .64
Hypercholesterolemia 132 (51.0) 61 (59.0) .16
Prior myocardial infarction 28 (10.7) 5 (4.8) .08
Body mass index, median (IQR), kg/m2 26.7 (24.5-29.4) 27.7 (25.2-30.4) .19
Infarct localization .89
Anterior 99 (37.9) 38 (36.5)
Inferior 98 (37.5) 38 (36.5)
Lateral 64 (24.5) 28 (26.9)
Killip class .97
I 213 (81.6) 85 (81.7)
II 48 (18.4) 19 (18.3)
Heart rate, median (IQR), beat/min 73 (61-84) 75 (62-90) .24
Blood pressure, median (IQR), mm Hg
Systolic 140 (120-150) 135 (120-150) .32
Diastolic 80 (70-85) 80 (70-85) .50
Pain onset to admission time interval, median (IQR), h 22.5 (14.0-39.5) 23.0 (15.0-32.5) .93
Pain onset to randomization time interval, median (IQR), h 23.3 (15.9-40.2) 23.5 (16.4-34.3) .70
Final infarct size (% of left ventricle) 10.0 (1.0-22.0) 10.0 (3.0-21.7) .99
Data are presented as number of patients (percentage) unless otherwise specified. IQR, Interquartile range.
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80 years with diagnosis of STEMI: chest pain episode lasting
z20 minutes between 12 to 48 hours before presentation and
ST-segment elevation z0.1 mV in z2 adjacent limb leads or
z0.2mV inz2 contiguous precordial leads or new pathologic Q
waves on surface electrocardiogram. Detailed exclusion criteria
as well as the details of assignment to either a conservative or
invasive strategy were reported in the primary study.7 Briefly,
using a computer-generated randomization sequence, we
randomly assigned patients to one of the treatment arms:
invasive or conservative. All patients received a loading dose of
clopidogrel (300-600 mg) or ticlopidine (500 mg) and 500 mg of
aspirin as well as an intravenous bolus of heparin. Patients
assigned to the conservative group received an intravenous
infusion of unfractionated heparin or subcutaneous low-molec-
ular-weight heparins for at least 24 hours. Patients assigned to
invasive arm received abciximab (ReoPro, Lilly Pharma Pro-
duktion, Hamburg, Germany) during and after the procedure as
an intravenous bolus of 0.25mg/kg of bodyweight followed by a
12-hour infusion of 0.125 Ag/kg per minute.
All patients in this study received clopidogrel 75 mg/d or
ticlopidine 500 mg/d for at least 4 weeks and aspirin 200 to
325 mg daily, indefinitely. Other drugs used were h-blockers,
angiotensin-converting enzyme inhibitors, and statins.
Scintigraphic study
Two participating centers (Deutsches Herzzentrum, Munich,
Germany, and Division of Cardiology, Careggi Hospital,
Florence, Italy) had logistic facilities to perform a scintigraphic
examination before randomization without significant delay in
study protocol and patient treatments, and had participated in
the BRAVE-2 trial myocardial salvage substudy. The BRAVE-2trial eligible patients who consented to participate in the study
underwent tracer (technetium Tc 99m sestamibi) injection
before randomization. Thereafter, single-photon emission
computed tomography (SPECT) image acquisition was
obtained immediately in patients randomized to conservative
strategy and after reperfusion in patients randomized to
invasive strategy. A follow-up SPECT study at rest was
performed 5 to 10 days later. The methods of data acquisition
and processing as well as infarct size measurement have
previously been described in detail.8 Three parameters were
obtained: area at risk (perfusion defect in the initial scintigra-
phy), final infarct size (perfusion defect in the follow-up
scintigraphy), and myocardial salvage index (area at risk minus
final infarct size divided by initial perfusion defect). The first 2
parameters were expressed as percentage of the left ventricle.
All studies were processed and measured in the scintigraphic
core laboratory by experienced operators who were blind to
group assignment and to which scan was performed before
and which after.
Definitions and study end point
Classification of anterograde coronary flow in the infarct-
related artery was done according to TIMI classification.9
Collateral circulationwas quantified according to Rentrop et al.10
After discharge, trained personnel blinded to patient’s
allocation performed detailed telephone interviews at 30 days
after randomization with each patient. For each event
reported, evidence was sought from hospital case records or
family physician. Myocardial salvage index, or the proportion
of initial perfusion defect salvaged by reperfusion and
calculated by paired scintigraphic studies, was the primary
end point of this study.
Table II. Baseline characteristics of patients randomized to invasive or conservative strategy
Characteristic Invasive group (n = 131) Conservative group (n = 130) P
Age, median (IQR), y 65.7 (57.7-74.2) 66.0 (54.4-73.7) .73
Women 34 (26.0) 34 (26.0) .97
Arterial hypertension 89 (68.0) 90 (69.0) .82
Diabetes 29 (22.0) 32 (25.0) .63
Current smoker 45 (34.0) 49 (38.0) .57
Hypercholesterolemia 68 (52.0) 64 (49.0) .66
Prior myocardial infarction 14 (10.7) 14 (10.8) .98
Prior aortocoronary bypass surgery 7 (5.3) 10 (7.7) .44
Body mass index, median (IQR), kg/m2 26.6 (24.8-29.1) 26.9 (24.2-29.7) .80
Infarct localization
Anterior 51 (39.0) 48 (37.0) .83
Inferior 48 (37.0) 50 (38.0) .86
Lateral 32 (24.0) 32 (25.0) .92
Killip class
I 107 (81.7) 106 (81.5) .91
II 24 (18.3) 24 (18.5) .91
Heart rate, median (IQR), beat/min 72 (61-83) 74 (61-84) .31
Blood pressure, median (IQR), mm Hg
Systolic 140 (120-150) 135 (120-150) .32
Diastolic 80 (70-86) 80 (70-85) .65
Pain onset to admission time interval, median (IQR), h 22.0 (14.1-40.3) 22.8 (13.8-38.3) .84
Pain onset to randomization time interval, median (IQR), h 22.5 (15.7-40.9) 23.7 (15.9-39.6) .84
Data are presented as number of patients (percentage) unless otherwise specified.
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Sample size calculation was performed based on the primary
end point of the study. In patients assigned to the invasive
strategy, we expected to achieve at least a 0.10 absolute
improvement in myocardial salvage index. Choosing a 2-sided a
level of .05 and power of 90%, 122 patients in each group were
needed. The overall number of patients enrolled was expanded
to 260 to accommodate for possible missing paired scinti-
graphic studies.
All analyses were done based on the intention-to-treat
principle. Because most of the continuous data were not
normally distributed, they are presented as median (interquar-
tile range). Categorical data are presented as counts or
proportions (percentage). The differences between the groups
were assessed using the v2 test or the Fisher exact test for
categorical data, and the nonparametric Wilcoxon rank sum
test for continuous data. A 2-tailed P value of less than .05 was
considered to indicate statistical significance. Statistical analysis
was performed using S-Plus version 4.5 statistical package
(S-PLUS, Insightful, Seattle, WA) for the statistical analyses.
Results
Patients’ characteristics
Of 365 patients of the BRAVE-2 trial, 261 recruited in
the predefined 2 centers had initial scintigraphy and
they constitute the cohort of this study. No significant
differences between the patients with initial scintigra-
phy and those without initial scintigraphy were ob-
served (Table I). Of 261 patients included in the study,
131 received invasive treatment and 130 received
conservative treatment on a randomized basis. Baselinedemographic and clinical characteristics of the patients
treated invasively and conservatively are shown in Table
II. All baseline characteristics appear to differ little
among patients treated invasively versus those treated
conservatively.
The angiographic and procedural characteristics of
patients who were assigned to the invasive group are
shown in Table III. After diagnostic angiography,
120 patients (91.6%) underwent coronary stenting,
6 patients (4.6%) had plain balloon angioplasty, 3 pa-
tients (2.3%) were sent to aortocoronary bypass graft
surgery, and 2 patients (1.5%) received no interventional
treatment because of an open infarct-related artery
without significant stenosis in angiogram. At the time of
angiography, 71 patients (54%) had residual blood flow
(TIMI flow grade z1) in the infarct-related artery.
Moreover, some degree of collateral circulation (collat-
eral grade z1) was observed in 40 patients (31%) in the
invasive group.
Scintigraphic data
Follow-up SPECT imaging was performed in 257
patients (97.5% of the entire study sample) after a
median of 8.1 days (6.9-9.5 days) after randomization.
Four patients in the conservative group did not undergo
follow-up SPECT imaging. The reasons were refusal in
2 patients and technical reasons (failure of dedicated
gamma camera) in 2 patients. In the conservative group,
11 patients (8.5%) underwent unplanned PCI before
performing the follow-up SPECT imaging. This was due




group (n = 130) P
Area at risk,
% of LV
17.0 (9.0-28.5) 16.0 (9.0-37.5) .99
Final infarct size,
% of LV
8.0 (2.0-16.0) 12.0 (3.2-25.0)4 .004
Myocardial salvage
index
0.44 (0.13-0.80) 0.23 (0.0-0.50)4 b.001
Data are presented as medians (25th-75th percentiles).
4Calculated in 126 patients who had the follow-up scintigraphic examinations.





Left main coronary artery 1 (0.8)
Left anterior descending artery 49 (37.0)
Left circumflex coronary artery 37 (28.0)
Right coronary artery 41 (31.0)
Venous bypass graft 3 (2)










Infarct-related vessel size, median (IQR), mm 2.67 (2.42-3.11)
Initial diameter stenosis, median (IQR), % 100.0 (67.0-100)
Treatment strategy
Stents 120 (91.6)
Balloon angioplasty 6 (4.6)
Aortocoronary bypass surgery 3 (2.3)
Medical therapy 2 (1.5)





Final diameter stenosis, median (IQR), % 8.2 (4.5-12.8)
Data are presented as number of patients (percentage) unless otherwise specified.
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heart failure in 2 patients, patient’s preference in
1 patient, and attending physician’s decision in 1 patient.
Scintigraphic data are shown in Table IV. The amount
of myocardium at risk or initial perfusion defect did
not differ significantly among the patients in the invasive
or conservative group. Final infarct size measured in
the follow-up scintigraphy was significantly smaller in
patients assigned to the invasive treatment versus those
assigned to the conservative group. Myocardial salvage
index, or the proportion of the initial perfusion defect
salvaged by the time of follow-up scintigraphy, was
almost 2 times greater among patients in the invasive
group compared with patients in the conservative
group (Table IV).
In the invasive group, salvage index was calculated in
groups with (TIMI flow grades 2 and 3; 61 patients) and
without (TIMI flow grades 0 and 1; 70 patients) residual
anterograde blood flow in the infarct-related artery.
Salvage index was 0.44 (0.15; 0.70) in the group with
TIMI flow grades 0 and 1 versus 0.43 (0.11; 0.85) in the
group with TIMI flow grades 2 and 3 (P = .88). In
patients with TIMI flow grade 0 and 1, salvage index was
calculated for patients with (Rentrop grades 2 and 3;13 patients) and without (Rentrop grades 0 and 1;
57 patients) collateral circulation. Salvage index was
0.60 (0.39; 0.80) in the group with Rentrop collateral
grades 2 and 3 versus 0.39 (0.12; 0.66) in the group with
Rentrop collateral grades 0 and 1 (P = .07).
In the invasive group, anterior infarct location (odd
ratio 0.72, P = .016) emerged as the only independent
predictor of myocardial salvage at stepwise multiple
linear regression analysis, which included all the
baseline clinical and angiographic variables, and
time intervals.
Clinical outcome
Thirty-day clinical outcome is shown in Table V.
One-month follow-up rate was 100%. During this period,
death, reinfarction, or stroke occurred in 3 patients
(2.3%) in the invasive group and 6 patients (4.6%) in the
conservative group (P = .30). One patient for each
group died after follow-up scintigraphy. Major bleeding
complications were observed in 3 patients (2.3%) of the
invasive group and 1 patient (0.8%) in the conservative
group (P = .32). During 30-day period, target vessel
revascularization was required in one patient (1%) in the
invasive group and 42 patients (32%) in the conservative
group (P b .001).
Discussion
The treatment of patients with acute STEMI arriving to
hospital beyond 12 hours after symptom onset, but
without symptoms of ongoing ischemia, represents a
challenging and unresolved issue. At present, there is
limited evidence-based rationale in favor of a reperfusion
strategy in patients presenting later than 12 hours after
symptom onset without persisting ischemia symptoms,
and current guidelines are not in favor of an invasive
treatment in these patients.11,12 The BRAVE-2 trial was
the first study to show that patients with STEMI
presenting between 12 and 48 hours after symptom
onset and treated with mechanical reperfusion (mostly
coronary stenting) had smaller infarct size than patients
treated conservatively.7







(n = 130) P
Death, myocardial
infarction, or stroke
3 (2.3) 6 (4.6) .30
Death 1 (0.8) 1 (0.8) .99
Myocardial infarction 2 (1.5) 4 (3.1) .40
Stroke 0 1 (0.8) .31
Major bleeding 3 (2.3) 1 (0.8) .32
Minor bleeding 11 (8.4) 1 (0.8) .003
Blood transfusion 5 (3.8) 1 (0.8) .10
Thrombocytopenia 1 (0.8) 0 .32
Target vessel
revascularization
1 (0.8) 42 (32.3) b.001
Data are presented as number of patients (percentage).
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patients with acute STEMI presenting 12 to 48 hours
after symptom onset is associated with an almost 2 times
greater myocardial salvage as compared with the
currently recommended conservative strategy. Thus,
data from this study demonstrate that myocardial salvage
is an important mechanism by which mechanical
reperfusion offers benefit in patients with STEMI
presenting beyond 12 hours from symptom onset.
Persistence of viable myocardium N12 hours from
coronary occlusion has been demonstrated3-6 and relat-
ed somehow to the residual blood flow to the area at
risk. Incomplete occlusion or intermittent reopening,13
and other factors such as ischemic preconditioning,14
residual blood flow in the infarct-related artery,6 or
recruitment of collaterals15,16 may prevent complete
necrosis and preserve viable myocardium. Other studies
have demonstrated the existence of stunned or hiber-
nating myocardium at the area at risk17,18 and that
hibernating myocardium may recover contractile func-
tion and that time window to salvage viable myocardium
and ameliorate adverse left ventricular remodeling may
be extended to weeks if collateral circulation is
present.19 In fact, our study also showed that patients
with preserved collateral circulation showed a strong
trend toward a greater myocardial salvage compared
with patients with absent collateral circulation. Other
investigators have demonstrated an association between
persistence of blood flow in the infarct-related artery and
reduced apoptotic cell death at the site of myocardial
infarction20 and that reperfusion reduces overall apo-
ptotic cell death although accelerates the apoptosis on
nonsalvageable cells.21 Furthermore, imaging studies
with fluorodeoxyglucose22 or rest-distribution thallium23
have demonstrated that residual viable myocardium after
acute myocardial infarction is associated with increased
mortality if patients were treated medically compared
with revascularized patients. Thus, evidence availableshows that viable myocardium is still present at the site
of infarction even late after symptom onset. The present
study demonstrated that mechanical reperfusion sal-
vages a greater proportion of this viable myocardium
compared with conservative treatment. The results of
the present study are consistent with those reported
from the STOPAMI-3 Study Investigators that docu-
mented that mechanical recanalization (coronary angio-
plasty or stenting) provides a substantial myocardial
salvage (myocardial salvage index of 0.52) in patients
with AMI considered ineligible for reperfusion therapy
because of presentation after 12 hours of symptom
onset.24
The present trial was not powered to draw conclu-
sions on clinical outcome, and the patient population
was relatively small and at low risk because of exclusion
criteria. However, we expect a greater invasive-strategy
clinical benefit in patients at higher risk.
The enrollment of patients with prior myocardial
infarction might potentially represent a limitation of our
study. However, the incidence was not only equal in the
2 groups, but was also low in absolute terms. Moreover,
after excluding patients with prior myocardial infarction
from myocardial salvage analysis the results did not
change.
The additive beneficial effects of abciximab in patients
with STEMI treated with mechanical reperfusion, al-
though difficult to quantify, deserve consideration.
Abciximab enhanced myocardial salvage when used in
conjunction with PCI in patients with acute STEMI
presenting within 12 hours.25,26
An interesting and not fully understood finding of this
study is that myocardial salvage was also evidenced in
the patients who underwent conservative treatment,
although half as much as in patients who received
mechanical reperfusion. Specifically, in patients treated
conservatively, the salvage index values showed that one
fifth to one fourth of the area at risk was salvaged. The
exact factors that enabled the myocardial salvage in
these patients remain largely unknown. One factor
might be the efficacy of conservative therapy to salvage
ischemic myocardium. Previous studies have demon-
strated that aspirin27 and h-blockers28 improve survival
in patients with acute myocardial infarction. It has
experimentally been demonstrated that beta-adrenergic
blockade early after coronary occlusion results in
substantial enhancement of the salvaged myocardium
achieved by reperfusion.29 Furthermore, clinical studies
have demonstrated that heparin30 and clopidogrel,31
both part of therapy in conservatively treated patients,
increase the patency rates in the infarct-related artery.
Spontaneous or therapy-facilitated coronary reopening
and subsequent reperfusion might result in myocardial
salvage in patients treated conservatively. In patients
with STEMI presenting within the first 12 hours from the
symptom onset, the presence of some residual blood
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34% of patients.32 In the present study, initial angiogra-
phy in patients treated invasively showed that 54% of the
patients had some residual blood flow in the infarct-
related artery, demonstrating that the proportion of
patients with preserved blood flow in the infarct-related
artery is increased with the increase in time from the
symptom onset. Although we have no data on the
residual blood flow in patients treated conservatively,
the randomized design of the study allows anticipation
of similar rates of spontaneous or therapy-facilitated
coronary reperfusion among patients treated conserva-
tively as well.
Conclusion
An invasive strategy based on coronary stenting with
adjunct use of abciximab leads to a substantial myocar-
dial salvage in patients with acute STEMI presenting
between 12 and 48 hours after the symptom onset.
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